A unit of Rostec, Russia's state corporation, has inked a pact with the Serum Institute of India to locally produce several vaccines in Russia, the Pharma Letter reports, a development that could bring about "significant losses" for Pfizer and GlaxoSmithKline in the country.
South Korea's EuBiologics has won World Health Organization approval as the third company to supply oral cholera vaccines for its global campaign just as a massive effort in Iraq ended, leaving stocks nearly depleted.
Beijing-based Sinovac Biotech has won a China FDA new drug certificate and production license approval for its Enterovirus 71 vaccine to prevent hand, foot and mouth disease (HFMD), marking the second go-ahead in the space in a month.
Indonesia may allow higher foreign investment in drug companies as Kalbe Farma and state-run Kimia Farma moved to build active pharmaceutical ingredient plants to combat persistent raw material shortages.
The U.S.-India Business Council wrapped up a medical device trade mission to the subcontinent just before Christmas and said the sector in India must develop an "innovate in India" mindset to go along with the country's efforts to draw in manufacturers under its "Make in India" trade campaign.
Samsung Group's pharmaceutical division appears to be betting the farm on a plan to be the go-to guy when it comes to actually making biosimilar drugs, eschewing contract research and becoming the leading contract manufacturer of them.
The globe's largest clinical research organization is looking to India as a source for the next waves of biosimilars as $55 billion worth of biotech drugs face patent expirations.
GlaxoSmithKline is teaming up with researchers from Monash University in Melbourne, Australia, to develop new manufacturing methods to make vaccines cheaper for children in the developing world.
Syngene International, the custom research arm of India's Biocon, said it will build a $100 million facility in the country's Mangaluru Special Economic Zone to make ingredients for pharmaceuticals and chemicals for the agricultural sector.
Bangladesh, about the geographic size of Iowa, could soon be independent of the rest of the world when it comes to supplying medicines to its dense population of 166 million people, about half that of all of the United States.